Synlogic, Inc. (NASDAQ:SYBX)’s share price fell 8% on Tuesday . The stock traded as low as $3.58 and last traded at $4.04. 511,504 shares were traded during trading, a decline of 69% from the average session volume of 1,637,697 shares. The stock had previously closed at $4.39.
Several research firms recently weighed in on SYBX. Chardan Capital lifted their price objective on shares of Synlogic from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, January 13th. Zacks Investment Research lowered shares of Synlogic from a “buy” rating to a “hold” rating in a research note on Wednesday, January 20th.
The stock’s 50 day simple moving average is $3.87 and its two-hundred day simple moving average is $2.59. The stock has a market cap of $140.73 million, a P/E ratio of -2.48 and a beta of 2.20.
Synlogic Company Profile (NASDAQ:SYBX)
Synlogic, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Recommended Story: Why do commodities matter?
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.